long-Term Real-World outcomes of Anti-VEGF Treatment in Early Good Responders with Neovascular Age-Related Macular Degeneration

Basit Öğe Kaydı
dc.contributor.authorBektas, Caglar
dc.contributor.authorOzdemir, Huseyin Baran
dc.contributor.authorKepez Yildiz, Burçin
dc.contributor.authorGürelık, İhsan Gökhan
dc.contributor.authorO¨zdek, Šengül C.
dc.date.accessioned2026-02-03T11:53:35Z
dc.date.available2026-02-03T11:53:35Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: To evaluate long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) that responded favorably to initial anti-VEGF loading therapy. Materials and Methods: This retrospective study included 55 eyes of 55 patients with at least 12 months of follow-up. Early good responders (EGR) were defined as those who showed ?5 letter gain in BCVA, complete resolution of intraretinal/subretinal fluid, reduction in lesion size, and disappearance of subretinal hemorrhage after three loading injections. Retreatments were guided by visual decline, fluid on OCT, or persistent/new hemorrhage. Results: The mean baseline BCVA improved from 51.1 ± 22.6 letters to 63.9 ± 21.5 after loading and was 58.5 ± 23.1 at the end of year-5 (p<0.001 and p=0.003 vs. baseline). Although BCVA decreased between month 3 and year 1 (p=0.009), it remained stable thereafter. Central foveal thickness decreased significantly from 327.9 ± 166.9 µm to 195.3 ± 97.1 µm post-loading and to 175.7 ± 59.6 µm at final visit (p<0.001). The mean annual number of injections declined from 5.1 in year 1 to 2.4 in year 5. Visual decline after loading was seen in 51% of eyes, mostly due to lesion activity (57%) or atrophy (43%). Notably, 27.2% of eyes required no further injections after the loading phase during the first year. No cases of tachyphylaxis or treatment switch were observed. Conclusions: EGR patients with nAMD can sustain functional and anatomical improvements over 5 years with significantly fewer injections. A substantial subset may require minimal or no additional treatment following initial therapy. © © 2025 The author(s). This is an open-access article under the terms of the Creative Commons Attribution License (CC BY).
dc.identifier.doi10.37845/ret.vit.2025.34.41
dc.identifier.endpage302
dc.identifier.issn1300-1256
dc.identifier.issue4
dc.identifier.scopus2-s2.0-105025824403
dc.identifier.scopusqualityQ4
dc.identifier.startpage293
dc.identifier.urihttps://doi.org/10.37845/ret.vit.2025.34.41
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34249
dc.identifier.volume34
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherGazi Eye Foundation
dc.relation.ispartofRetina-Vitreus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20260130
dc.subjectAge-related macular degeneration
dc.subjectAnti-VEGF
dc.subjectearly good responders
dc.subjectlong-term results
dc.subjectneovascular AMD
dc.titlelong-Term Real-World outcomes of Anti-VEGF Treatment in Early Good Responders with Neovascular Age-Related Macular Degeneration
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu